TD Cowen Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
TD Cowen analyst Tyler Van Buren maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares closed ...
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
The Pharma Letter22h
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...